Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-
mediated immunity. To facilitate prospective surveillance for such evolution, we map how …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Waves of SARS-CoV-2 infection have resulted from the emergence of viral variants with
neutralizing antibody resistance mutations. Simultaneously, repeated antigen exposure has …

The emergence of SARS-CoV-2 variants with mutations in key antibody epitopes has raised
concerns that antigenic evolution will erode immunity. The susceptibility of immunity to viral …

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …